 Despite the fact that a substantial response rate may be obtained in small-cell lung cancers using double-drug chemotherapy: cisplatin-etoposide, PE, a cure remains an exception. More aggressive regimens remain controversial and recent attempts at increasing dose-intensity have been restricted to patients with a more favourable presentation. 